

# ARQULE - Positive Data in HCC is an Add-On!

https://marketpublishers.com/r/ABB8653DADDEN.html Date: January 2012 Pages: 3 Price: US\$ 140.00 (Single User License) ID: ABB8653DADDEN

## **Abstracts**

Positive PhII data of Tivantinib (formerly ARQ-197, c-MET inhibitor) in 2nd line HepatoCellular Carcinoma (HCC) expands the opportunity as there are no FDA approved drugs available for this indication. Tivantinib showed statistically significant improvement of 56% in time-to-progression (TTP) in the intent-to-treat (ITT previously treated HCC pts) with a hazard ratio (HR) of 0.64 (p-value = 0.04). Moreover, failure of BMY's Brivanib (PhIII, HCC 2nd line) to fulfill this unmet need raises expectations and the efficacy bar for Tivantinib. We remain positive on an approval of Tivantinib in its lead indication – NSCLC by 2014 and have assigned peak sales of... For more details, please read our report released on 19th January, 2012 on ArQule titled "Positive Data in HCC is an Add-On!"



### **Contents**

#### **COMPANIES MENTIONED**

ARQULE



#### I would like to order

Product name: ARQULE - Positive Data in HCC is an Add-On! Product link: https://marketpublishers.com/r/ABB8653DADDEN.html Price: US\$ 140.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/ABB8653DADDEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970